Brief: Medivir's Partner Tango Therapeutics Receives FDA Clearance
11/09/2023 14:22
Sept 11 (Reuters) - Medivir AB MEDIVIR.ST :
* MEDIVIR'S PARTNER TANGO THERAPEUTICS RECEIVED FDA
CLEARANCE TO
START THE TNG348 PHASE 1/2 CLINICAL STUDY
* TANGO THERAPEUTICS INTENDS TO INITIATE A PHASE 1 / 2 STUDY
WITH
TNG348 IN FIRST HALF OF 2024
Source text for Eikon: ID:nWkr4z3TwC
Further company coverage: MEDIVIR.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))